Clinical trial · no report yet · Phase 3
NCT05048797
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
- NCT05048797 ↗
- Active not recruiting
- AstraZeneca
- 102 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 43 | |
| Podcasts | 31 | |
| YouTube | 27 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Interventions
- Trastuzumab Deruxtecan; Cisplatin; Carboplatin; Pembrolizumab; Pemetrexed
- Arms
- Arm 1 · Experimental
- Arm 2 · Active comparator
- Enrollment
- 454
- Primary outcomes
- Progression Free Survival (PFS) by Blinded Independent Central Review (BICR)
- Sponsor
- AstraZeneca with Daiichi Sankyo
- Start
- Oct 28, 2021
- Primary completion
- Jun 9, 2026
- Results posted
- No
- Registry record
- NCT05048797 · updated Jul 10, 2026